EVGN.TA
Evogene Ltd
Price:  
470.90 
ILS
Volume:  
81,504.00
Israel | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

EVGN.TA WACC - Weighted Average Cost of Capital

The WACC of Evogene Ltd (EVGN.TA) is 6.7%.

The Cost of Equity of Evogene Ltd (EVGN.TA) is 6.65%.
The Cost of Debt of Evogene Ltd (EVGN.TA) is 7.00%.

Range Selected
Cost of equity 5.50% - 7.80% 6.65%
Tax rate 0.10% - 0.10% 0.10%
Cost of debt 7.00% - 7.00% 7.00%
WACC 5.5% - 7.8% 6.7%
WACC

EVGN.TA WACC calculation

Category Low High
Long-term bond rate 1.6% 2.1%
Equity market risk premium 5.9% 6.9%
Adjusted beta 0.65 0.75
Additional risk adjustments 0.0% 0.5%
Cost of equity 5.50% 7.80%
Tax rate 0.10% 0.10%
Debt/Equity ratio 0.01 0.01
Cost of debt 7.00% 7.00%
After-tax WACC 5.5% 7.8%
Selected WACC 6.7%

EVGN.TA's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for EVGN.TA:

cost_of_equity (6.65%) = risk_free_rate (1.85%) + equity_risk_premium (6.40%) * adjusted_beta (0.65) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.